Correlación clínico-histopatológica del cáncer de próstata localmente avanzado y la angiogénesis
Contenido principal del artículo
Resumen
Se ha buscado desarrollar nuevos marcadores biológicos que permitan una evaluación más exacta del cáncer de próstata. Uno de los más novedosos es la densidad microvascular, o angiogénesis, que debe de ser evaluada como factor pronóstico en pacientes con cáncer de próstata localmente avanzado.
Detalles del artículo
Sección
Cómo citar
Referencias
Izawa J I, Dinney CPN. The role of angiogenesis in prostate and other urologic cancers: a review. Can Med Assoc J 2001; 164(5): 662-70.
Jiménez MA, Ochoa FJ. Primer consenso nacional sobre el manejo del cáncer de próstata T3; 2003.
Brawer MK. Quantitative microvessel density: a staging and prog- nostic marker for human prostatic carcinoma. Cancer 1996; 78: 345-9.
Mistry K, Cable G. Meta-Analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003; 16: 95-101.
Reiter RE, de Kernion JB. Epidemiología, etiología y prevención del cáncer de próstata. Campbell's Urology. 8a. Ed. Vol. 4: Baltimore: Editorial Médica Panamericana; 2005, p. 3287-311.
Song JM, Kim CB, Chung HC, Kane RL. Prostate-specific antigen, digital rectal examination and transrectal ultrasonography: A meta-analy- sis for this diagnostic triad of prostate cancer in symptomatic Korean Men. Yonsei Med J 2005; 46(3): 414-24.
Van Moorselaar RJ, Voest EE. Angiogénesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 2002; 197(1-2): 239-50.
Trojan L, Michel MS, Rensh F, Hackson DG, Alken P, Grobholz R. Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1). J Urol 2004; 172: 103-7.
Chung LWK, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenviron- ment. J Urol 2005; 173: 10-20.
Charlesworth PJS, Harris AL. Mechanisms of disease: Angioge- nesis in urologic malignancies. Nat Clin Pract Urol 2006; 3(3): 157-69.
Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angio- genesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the pros- tate. Cancer 1997; 79: 772-9.
Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothe- lial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165: 688-93.
Moy YP, Sessa WC, Weiss RM. Inhibition of angiogenesis and tumor growth in human prostate cancer LNCaP cells with the inhibition of endothelial nitric oxid. J Urol 1999; 161(4S): 130.
Liu XH, Kirchenbaum A. Inhibition of cyclooxygenase-2 supres- se angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;
: 820-5.
Eastham JA, Scardino PT. Prostatectomía Radical. Campbell's urology. 8a. Ed. Vol. 4: Baltimore: Editorial Médica Panamericana; 2005, p. 3375-3403.
Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in inmunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-80.
Ferrer FA, Miller LJ, Andrawis RI. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997; 157: 2329-33.
Carter HB, Partin AW. Diagnóstico y estadificación del cáncer de próstata. Campbell's Urology. 8a. Ed. Vol. Baltimore: Editorial Médica Panamericana; 2005, p. 3348-74.